Indian drugmakers urged to tap cancer market and innovation

7 February 2019
india_big-1

Shifting focus from generic drugs to specialty drugs amidst continued price erosion in the USA, Indian drug majors have started working towards having enough cancer-fighting drugs in their product pipeline, reflecting a global trend where companies are rushing to tap a market that is estimated to touch $138 billion worldwide this year, reports The Pharma Letter’s India correspondent.

Recent progress in biological therapies has widened the scale of therapeutic targets for the treatment of cancer with the identification of tumor cell specific genes. While immunotherapies and biologics are emerging as potential therapies to find a permanent cure for various cancers, officials say amongst various biologics, drugs based on monoclonal antibodies (MAbs) have gained significant attention, further propelling the growth of the oncology drugs market.

"All the big multinationals like Glaxo, Merck and Pfizer are co-developing and co-commercializing new immunotherapy candidates which have potential in fighting difficult-to-treat cancers. They are intent on boosting their oncology pipelines. It is time India does too," said an Indian Drug Manufacturers Association (IDMA) official.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical